



(11) **EP 2 132 209 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
16.04.2014 Bulletin 2014/16

(45) Date of publication and mention
of the grant of the patent:
12.02.2014 Bulletin 2014/07

(21) Application number: **08718797.7**

(22) Date of filing: **19.03.2008**

(51) Int Cl.:
C07D 473/18 ^(2006.01) **A61K 31/522** ^(2006.01)
A61P 37/00 ^(2006.01)

(86) International application number:
PCT/GB2008/000958

(87) International publication number:
WO 2008/114008 (25.09.2008 Gazette 2008/39)

(54) **9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7)
MODULATORS**

9-SUBSTITUIERTE 8-OXOADENINVERBINDUNGEN ALS MODULATOREN DES TOLL-LIKE-
REZEPTORS (TLR7)

COMPOSÉS 8-OXO-ADENINE 9 SUBSTITUÉ COMME MODULATEURS DU RÉCEPTEUR DE TYPE
TOLL (TLR7)

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

(30) Priority: **19.03.2007 US 895529 P**

(43) Date of publication of application:
16.12.2009 Bulletin 2009/51

(73) Proprietors:
• **AstraZeneca AB**
151 85 Södertälje (SE)
• **Dainippon Sumitomo Pharma Co., Ltd.**
Osaka 541-8524 (JP)
Designated Contracting States:
CH DE ES FR GB HR IS IT LI LT LV MT NO PL SE

(72) Inventors:
• **BONNERT, Roger, Victor**
Loughborough
Leicestershire LE11 5RH (GB)
• **MCINALLY, Thomas**
Loughborough
Leicestershire LE11 5RH (GB)
• **THOM, Stephen**
Loughborough
Leicestershire LE11 5RH (GB)

(74) Representative: **Curran, Sally Ann et al**
AstraZeneca Intellectual Property,
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)

(56) References cited:
EP-A- 1 728 793 WO-A1-2007/034881
WO-A1-2007/034882 WO-A1-2007/034916

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).